2015年肾脏病重要研究进展

doi:10.3969/j.issn.1004-583X.2016.02.008

临床荟萃 ›› 2016, Vol. 31 ›› Issue (2): 168-174.doi: 10.3969/j.issn.1004-583X.2016.02.008

2015年肾脏病重要研究进展

徐金升,何雷,张胜雷

河北医科大学第四医院肾内科,河北石家庄 050011

收稿日期:2016-01-07 出版日期:2016-02-05 发布日期:2016-04-18
通讯作者: 徐金升, Email: xjs5766@126.com
作者简介:徐金升，男，主任医师、教授、医学博士、博士研究生导师。现任职务：河北医科大学第四医院副院长、肾内科主任。荣誉称号：河北省有突出贡献中青年专家。学术兼职：中国医师协会肾脏内科医师分会委员，中国医院协会血液净化中心管理分会委员，河北省血液净化专业质量管理与控制中心主任，河北省医院协会血液净化中心管理分会主任委员，河北省医学会肾脏病学分会副主任委员，河北省医师协会肾脏内科医师分会副主任委员，河北省中西医结合肾脏病学分会副主任委员，河北省医学工程学会副理事长，河北省医学会常务理事，河北省医院协会常务理事。学术成就：承担省厅级科研课题11项；发表论著100余篇，其中SCI收录15篇，主编专著2部；获河北省科学技术奖二等奖1项、三等奖2项，河北省医学科技奖一等奖3项。

Major progress in kidney disease in 2015

Xu Jinsheng, He Lei, Zhang Shenglei

Department of Nephrology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China

Received:2016-01-07 Online:2016-02-05 Published:2016-04-18
Contact: Xu Jinsheng, Email: xjs5766@126.com

摘要/Abstract

摘要： 在过去的2015年,有关肾脏病发病危险因素、原发性肾脏病和继发性肾脏病诊疗等方面有了长足的进步。本文就有关判断肾脏病发生、预后的生物学标志物、原发性肾脏病、继发性肾脏病及其并发症的部分相关诊疗进展进行了综述。

关键词: 肾脏病学, 肾小球肾炎, 膜性, 高血压, 成纤维细胞生长因子

Abstract: In the past 2015, several aspects in kidney disease have increased dramatically, including the risk factors in kidney disease, diagnosis and treatment in primary and secondary kidney disease. The review describes the particularly progress in the biomarker of predictor and outcome of kidney disease, the diagnosis and treatment of primary kidney disease, secondary kidney disease and related complications.

Key words: nephrology, glomerulonephritis,membranous, hypertension, fibroblast growth factors

中图分类号:

R692

徐金升,何雷,张胜雷. 2015年肾脏病重要研究进展[J]. 临床荟萃, 2016, 31(2): 168-174.

Xu Jinsheng, He Lei, Zhang Shenglei. Major progress in kidney disease in 2015[J]. Clinical Focus, 2016, 31(2): 168-174.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.02.008

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I2/168

参考文献

[1] Yano Y, Fujimoto S, Kramer H, et al. Long-term blood pressure variability, new-onset diabetes mellitus, and new-onset chronic kidney disease in the Japanese general population[J]. Hypertension, 2015, 66(1): 30-36.
[2] Inker LA, Okparavero A, Tighiouart H, et al. Midlife blood pressure and late-life GFR and albuminuria: an elderly general population cohort[J]. Am J Kidney Dis, 2015, 66(2): 240-248.
[3] Hayek SS, Sever S, Ko YA, et al. Soluble urokinase receptor and chronic kidney disease[J]. N Engl J Med, 2015, 373(20):1916-1925.
[4] Rebholz CM, Grams ME, Coresh J, et al. Serum fibroblast growth factor-23 is associated with incident kidney disease[J]. J Am Soc Nephrol, 2015, 26(1): 192-200.
[5] Tesar V, Troyanov S, Bellur S, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study[J]. J Am Soc Nephrol, 2015, 26(9): 2248-2258.
[6] Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy[J]. N Engl J Med, 2015, 373(23): 2225-2236.
[7] Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy[J]. Am J Kidney Dis, 2015, 66(5): 783-791.
[8] Kao L, Lam V, Waldman M, et al. Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 2015, 26(2): 291-301.
[9] Fresquet M, Jowitt TA, Gummadova J, et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy[J]. J Am Soc Nephrol, 2015, 26(2): 302-313.
[10] Khan S, Bolton WK. Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2014, 9(6): 1001-1004.
[11] van den Brand JA, van Dijk PR, Hofstra JM, et al. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2014, 9(6): 1066-1073.
[12] Caro J, Gutierrez-Solis E, Rojas-Rivera J, et al. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus[J]. Nephrol Dial Transplant, 2015, 30(3): 467-474.
[13] Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy[J]. J Am Soc Nephrol, 2015, 26(10): 2545-2558.
[14] Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care[J]. Lancet, 2015, 385(9981): 1983-1992.
[15] Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort[J]. Arthritis Rheumatol, 2015, 67(5): 1305-1313.
[16] Guideline development group. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min)[J]. Nephrol Dial Transplant, 2015, 30 (Suppl 2): ii1-142.
[17] Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study[J]. Am J Kidney Dis, 2010, 55(3): 441-451.
[18] Rossignol P, Massy ZA, Azizi M, et al. The double challenge of resistant hypertension and chronic kidney disease[J]. Lancet, 2015, 386(10003): 1588-1598.
[19] Van Buren PN, Lewis JB, Dwyer JP, et al. The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial[J]. Am J Kidney Dis, 2015, 66(3): 479-488.
[20] Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis[J]. J Am Soc Nephrol, 2015, 26(2): 493-503.
[21] Yamamoto T, Shoji S, Yamakawa T, et al. Predialysis and postdialysis pH and bicarbonate and risk of all-cause and cardiovascular mortality in long-term hemodialysis patients[J]. Am J Kidney Dis, 2015, 66(3): 469-478.
[22] Schutte E, Lambers Heerspink HJ, Lutgers HL, et al. Serum bicarbonate and kidney disease progression and cardiovascular outcome in patients with diabetic nephropathy: a post hoc analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin Ⅱ Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial)[J]. Am J Kidney Dis, 2015, 66(3): 450-458.
[23] Yang L, Xing G, Wang L, et al. Acute kidney injury in China: a cross-sectional survey[J]. Lancet, 2015, 386(10002): 1465-1471.
[24] Grams ME, Sang Y, Ballew SH, et al. A meta-analysis of the association of estimated GFR, albuminuria, age, race, and sex with acute kidney injury[J]. Am J Kidney Dis, 2015, 66(4): 591-601.
[25] James MT, Grams ME, Woodward M, et al. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury[J]. Am J Kidney Dis, 2015, 66(4): 602-612.
[26] Barry R, James MT. Guidelines for classification of acute kidney diseases and disorders[J]. Nephron, 2015, 131(4): 221-226.

2015年肾脏病重要研究进展

Major progress in kidney disease in 2015

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王涛, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗磷脂酶A2受体抗体与特发性膜性肾病的相关性[J]. 临床荟萃, 2023, 38(7): 606-612.
[2]	李志勇, 李星. 多模态超声在高血压患者大脑中动脉狭窄筛查中的临床价值[J]. 临床荟萃, 2023, 38(7): 613-617.
[3]	高秦宇, 包蓓艳, 金燕, 赵宇. IgA肾病合并抑郁状态患者的临床特征和预后影响因素分析[J]. 临床荟萃, 2023, 38(6): 510-515.
[4]	郭雨, 李永东. ARNI在高血压治疗中的研究进展[J]. 临床荟萃, 2023, 38(2): 181-184.
[5]	刘奕, 崔坤, 刘畅, 赵浩天, 李丽, 薛红元. 血清分泌型卷曲蛋白5水平与原发性高血压患者早期肾损害的相关性[J]. 临床荟萃, 2023, 38(12): 1073-1077.
[6]	江吉, 朱小刚, 姜山, 达哇扎巴, 岑强. 世居高原高血压人群蛋白尿相关危险因素[J]. 临床荟萃, 2023, 38(12): 1086-1090.
[7]	徐阳, 薛凌. H型高血压合并2型糖尿病患者轻度认知功能障碍的影响因素[J]. 临床荟萃, 2023, 38(10): 887-892.
[8]	杨晓蓉, 周淑红, 潘亮, 郭莉江. 结缔组织病相关肺动脉高压的发病机制及其筛查的研究进展[J]. 临床荟萃, 2023, 38(10): 944-948.
[9]	李瑞珍, 李星辉, 曾璟, 姚晓涛, 杨珂欣, 张展. 高血压认知功能障碍机制的研究进展[J]. 临床荟萃, 2023, 38(1): 88-92.
[10]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[11]	马洪珍, 张涛. 生物标志物评估老年慢性肾脏病患者心功能的研究进展[J]. 临床荟萃, 2022, 37(9): 855-859.
[12]	尹贻锟, 尹逊伟, 王佳林, 孙君志. 太极拳锻炼周期对原发性高血压的血压及心血管危险因素的影响:系统性评价和Meta分析[J]. 临床荟萃, 2022, 37(7): 599-606.
[13]	高鹏丽, 陈丽丽, 田芬, 张嘉倩, 陈怿鹏, 亓晓菁, 邢广群. 体质量指数对IgA肾病患者临床病理及预后的影响[J]. 临床荟萃, 2022, 37(3): 234-242.
[14]	邱建美, 王德峰. 恩格列净治疗2型糖尿病的研究现状[J]. 临床荟萃, 2022, 37(2): 170-173.
[15]	张鹏伟, 程霞, 程兰兰, 赵慧, 马志刚. 钠-葡萄糖协同转运蛋白2抑制剂对IgA肾病肾脏保护作用的研究进展[J]. 临床荟萃, 2022, 37(11): 1053-1056.